|
Following Success of Pilot, Cenix BioScience and Schering
AG enter into Agreement on Multiple RNAi-based Target Validation Projects Dresden, Germany,
October 25, 2005 - Cenix BioScience GmbH (Dresden), the leading specialist
in advanced RNA interference (RNAi)-based research services, today announced
that following the success of a pilot project started in late 2004, it has
entered into a new agreement with Schering AG to extend their target validation
partnership.
Started in late 2004, the pilot project focused on the application of Cenix’
combination of high throughput (HT) RNAi technology with multiplexed, high
content (HC) phenotypic analyses to efficiently generate detailed in vitro
validation data for over 100 target candidates in multiple mammalian cell types.
Having now completed this initial project and achieved all required performance
milestones, Cenix has clearly demonstrated its ability to enhance and accelerate
efforts towards prioritizing targets for further internal development.
As a result of this success, the two companies have now entered into a new
agreement, setting the terms under which Schering will outsource up to 6 more
projects of similar type, i.e. mandating Cenix to carry out HT-RNAi validation
programs in human cells to rapidly and efficiently screen through large
collections of target candidate genes previously identified by Schering.
“Though quite challenging, the first target validation project with Schering was
scientifically very gratifying and the overall interaction has been a true
pleasure for our team” said Dr. Christophe Echeverri, CEO/CSO of Cenix
BioScience. “We are excited by the prospect of continuing this work and look
forward to further contributing to such an excellent program.”
No financial terms were disclosed.
About Cenix BioScience GmbH
Cenix BioScience GmbH is a pioneer and leader in high throughput (HT),
genome-driven applications of RNA interference (RNAi) for the discovery and
validation of new therapeutic drug targets. Founded in 1999 as the first
biotechnology company specializing exclusively in HT-RNAi, Cenix has accumulated
unparalleled depth and breadth of experience in this field, combining high
content phenotypic analyses with proprietary genome-wide RNAi libraries for use
in key experimental systems, including a wide range of human and rodent cells.
Cenix is now making its unique expertise accessible to industry and academic
researchers through highly customizable research services. For more information
about Cenix, please visit the company’s website
www.cenix-bioscience.com.
|
